Search CSBR
CHAMPIONS ONCOLOGY, INC.
Nasdaq · CIK 771856
Last close4.94
Daily change+0.06 (1.23%)
10 Years gain+195.81%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CSBR · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 0430
Fundamental
22.7Momentum
1.6Acceleration
1.6Confidence
79.0Annual Revenue16
Quarterly Revenue49
Annual CFO15
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth4.6 / 25
Quality9.0 / 25
Capital Efficiency0.0 / 20
Balance Sheet8.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 2.1426 percentage points.
Operating margin compression · MEDIUMOperating margin compressed by 9.6841 percentage points.
Key Metrics
Revenue Growth TTM6.81%OK
Revenue CAGR 3Y3.33%OK
Gross Margin48%OK
Operating Margin-1.69%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y-23.58%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 FY Apr 30, 2026 | $59.43M | $28.53M | -$1.14M | -$4.47M | -$5.04M | 48% | -1.92% | -8.47% | n/a | 13.83M |
| 2026 FY Apr 30, 2025 | $56.94M | $28.56M | $4.55M | $7.39M | $7.00M | 50.15% | 8% | 12.29% | n/a | 14.27M |
| 2025 FY Apr 30, 2024 | $50.16M | $20.75M | -$7.36M | -$6.14M | -$6.97M | 41.38% | -14.67% | -13.9% | n/a | 13.55M |
| 2024 FY Apr 30, 2023 | $53.87M | $24.34M | -$5.26M | $3.97M | $1.10M | 45.18% | -9.76% | 2.04% | n/a | 13.54M |
| 2023 FY Apr 30, 2022 | $49.11M | $25.48M | $607,000.00 | $6.50M | $4.11M | 51.88% | 1.24% | 8.38% | 40.32% | 14.16M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $60.82M | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-061519, 0001628280-25-057082 |
| Revenue Growth TTM | 6.81% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-061519, 0001628280-25-057082 |
| Revenue CAGR 3Y | 3.33% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-049834 |
| Revenue CAGR 5Y | 7.68% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001628280-26-049834 |
| Gross Profit CAGR 3Y | 5.43% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-049834 |
| Operating Income Growth | -122.56% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001628280-26-061519, 0001628280-25-057082 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 48% | Gross Profit / Revenue | OK | 0001628280-26-061519, 0001628280-25-057082 |
| Operating Margin | -1.69% | Operating Income / Revenue | OK | 0001628280-26-061519, 0001628280-25-057082 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-061519 |
| Current Ratio | 1.03x | Current Assets / Current Liabilities | OK | derived |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001628280-26-049834 |
| Diluted EPS TTM | -$0.07 | Net income TTM / Diluted shares | OK | 0001628280-26-061519, 0001628280-25-057082 |